News & Updates
Filter by Specialty:
SGLT2 inhibitors score big, this time in gout
22 Jun 2023
byElvira Manzano
Patients initiated on gliflozins or flozins – also called sodium-glucose co-transporter 2 (SGLT2) inhibitors – for type 2 diabetes (T2D) who were previously on metformin had reductions in the incidents of gout of up to 60 percent compared with other second-line agents in a recent study.
SGLT2 inhibitors score big, this time in gout
22 Jun 2023Novel drug STRIDES in the right direction for knee OA
21 Jun 2023
byAudrey Abella
In the phase III STRIDES X-Ray Extension study, additional doses of the investigational CLK/DYRK inhibitor lorecivivint delivered favourable outcomes for individuals with advanced knee osteoarthritis (OA).